Ginkgo Bioworks launches ADME-One platform for early-stage screening - Drug Target Review

You bought that AI tool. Nobody used it. $200/month quietly canceled six months later. That's not failure. That's what happens when AI gets sold as a solution before anyone identifies the actual prob

You bought that AI tool. Nobody used it. $200/month quietly canceled six months later.

That's not failure. That's what happens when AI gets sold as a solution before anyone identifies the actual problem.

Here's what a biotech company just got right that most business owners miss entirely.

Ginkgo Bioworks built ADME-One to solve one specific, expensive bottleneck in drug development — early-stage screening. Not "all the things." One painful, costly, time-consuming thing. They layered AI on top of a process that already existed and made that process faster and more predictable.

That's the blueprint worth stealing.

The businesses winning with AI right now aren't replacing their operations. They're finding the single workflow that eats the most time or produces the most errors — and dropping AI into that one spot.

You don't need a consultant. You don't need a six-month implementation plan.

This week, write down the one task your team repeats most that produces inconsistent results. That's your starting point. One problem. One test. Measurable within 30 days.

That's how AI earns its place in your business — not through hype, through proof.

What's the one repetitive process in your business that still feels more painful than it should?

#AIStrategy #SmallBusiness #BusinessGrowth #AIImplementation

Original Source

Ginkgo Bioworks has launched ADME-One, an integrated platform combining high-throughput ADME testing with AI-powered human pharmacokinetic ...